Established:

2005

Employees:

25

Distinctiveness:

QMFC technology for the producing of recombinant antibodies, HybriFree technology for the development of recombinant antibodies patented by Icosagen

Export audience:

Drug developers, pharmacy and biotechnology companies, as a rule

Services:

Provision of service for the development of recombinant antibodies and producing of protein according to the orders of the customers, directed towards the European and US markets

Areas of activity:

Development of new technologies, development of cell production systems for drug development and marketing of developed technologies

Locations of activity:

Europe, the USA

Academic cooperation partners:

We have close cooperation with Estonian (University of Tartu, Tallinn University of Technology, Estonian University of Life Sciences) as well as foreign (KU Leuven, University of Helsinki, Karolinska Institute, INSERM, etc.) universities